Biocon Limited · NSE:BIOCON
Biocon — Q3 FY24 Earnings Presentation
19 slides from Biocon's earnings presentation, Feb 9, 2024
Slide 1: Q3 FY24 Earnings Call
Q3 FY24 Earnings Call February 9th, 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Group CEO Opening Remarks
Group CEO Opening Remarks BS Biocon
Slide 4: Financial Highlights Q3 FY24
Financial Highlights Q3 FY24
Slide 5: Financial Highlights: Q3 FY24
Financial Highlights: Q3 FY24 Consolidated (in ₹ Cr.) Q3 FY24 Q3 FY23 YoY % Total Revenue1 4,519 3,020 50 Biosimilars +65% | Research +9% | Generics -7% Core EBITDA2 983 1,069 (8) % Margin 27% 36% Net R&D spend at ₹329 Cr, representing 11% of revenues ex- EBITDA 1,492 723 106 Syngene % Margin 33% 24
Slide 6: Financial Highlights: Q3 FY24
Financial Highlights: Q3 FY24 Consolidated (in ₹ Cr.) Q3 FY24 Q3 FY23 YoY % Net Profit 644 140 360 (before exceptional items) Exceptional items: • Q3 FY24 • Gain on carrying value of existing contractual receivable arrangement; offset by Exceptional Items • Impairment of intangibles associated with
Slide 7: Generics Q3 FY24
Generics Q3 FY24
Slide 8: Biocon Generics: Q3 FY24 Highlights
Biocon Generics: Q3 FY24 Highlights Q3 Q3 Q2 YoY QoQ In INR Cr FY24 FY23 FY24 % % Consistent steady/ growth in Generic Formulations business Segment Revenue 703 760 676 (7) 4 Received first Generic Formulation approval in China, for Mycophenolate Core EBITDA 154 168 158 (8) 2 Sodium % of revenue 22%
Slide 9: Biosimilars Q3 FY24
Biosimilars Q3 FY24 gS Biocon Biologics
Slide 10: Biocon Biologics: Biosimilars – Q3 FY24 Business Update
Biocon Biologics: Biosimilars – Q3 FY24 Business Update Key Products’ Market Share1 United States Finished operational integration of acquired business from Viatris in about Nov-23 Aug-23 Nov-22 120 countries, one year ahead of schedule Fulphila (bPegfilgrastim) 18% 20% 11% Ogivri (bTrastuzumab) 12%
Slide 11: Biocon Biologics: Biosimilars – Q3 FY24 Financial Update
Biocon Biologics: Biosimilars – Q3 FY24 Financial Update Q3 Q3 Q2 In INR Cr YoY % QoQ % FY24 FY23 FY24 Excluding licensing revenues from the non-core BFI divesture, sequential Segment Revenue 2,483 1,507 1,969 65 26 growth of 8% Core EBITDA1 587 663 660 (11) (11) Core EBITDA margin impacted on accou
Slide 12: Biocon Biologics: Biosimilars – Q3 FY24 Other Business Updates
Biocon Biologics: Biosimilars – Q3 FY24 Other Business Updates Initiated Phase 3 studies for bPertuzumab Progressive discussion with the US FDA ; Awaiting site-inspection for bAspart and bBevacizumab BLA in US Key Catalysts Opening up of bAdalimumab market along with regulatory approvals for bAspart
Slide 13: Novels Q3 FY24
Novels Q3 FY24
Slide 14: Novel Molecules: Bicara Therapeutics
Novel Molecules: Bicara Therapeutics* $165 million Series C financing from dedicated biotech investors closed in Dec’23. Biocon recorded a dilution and fair value gain of ₹456 crores in the consolidated P&L statement during the quarter As of December 2023, Biocon’s shareholding in Bicara at 14%. *a
Slide 15: Research Services Q3 FY24
Research Services Q3 FY24 Syngene
Slide 16: Syngene: Q3 FY24 Update
Syngene: Q3 FY24 Update Positive performance in Development and Manufacturing Services as well as in In INR Cr Q3 FY24 Q3 FY23 YoY % the Dedicated Centers. Performance in Discovery Services was impacted by the slowdown in biotech funding Segment Revenue 854 786 9 EBITDA 261 248 5 In Manufacturing Se
Slide 17: Concluding Remarks
Concluding Remarks
Slide 18: Concluding Remarks: Q3 FY24
Concluding Remarks: Q3 FY24 Completion of transition and integration of the acquired biosimilars business; sustained momentum in product portfolio across markets augurs well for Biocon Biologics Generics Business making progress on expanding portfolio and geographic reach; strengthening its manufact
Slide 19: Q&A
Q&A